Stock Track | Novavax Plummets 5.04% Intraday as FDA Memo Links Child Deaths to COVID Vaccines

Stock Track12-02

Novavax's stock fell sharply by 5.04% during intraday trading on Monday, following a broader decline in vaccine-related stocks.

The drop came after a memo from the FDA's Dr. Vinay Prasad linked COVID-19 vaccines to the deaths of at least 10 children, citing heart inflammation as a probable cause. The memo also announced plans to tighten vaccine approval standards, raising concerns about future regulatory hurdles for Novavax and other vaccine makers.

Investors reacted negatively to the news, fearing that stricter regulations could limit vaccine sales and increase development costs. The FDA's stance, coupled with Health Secretary Robert F. Kennedy Jr.'s skepticism toward mRNA vaccines, has added uncertainty to the sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment